Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daisuke Tomizawa

Showing results (131-140 of 188) with videos related to

Pageof 19
Sort By:
Bone Marrow Transplantation|May 26, 2018
Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemiaMotohiro Kato, Mio Kurata, Junya Kanda, et al.
Leukemia|February 16, 2021
Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndromeTakashi Taga, Shiro Tanaka, Daisuke Hasegawa, et al.
International Journal of Hematology|September 19, 2020
Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysisMiharu Yabe, Tomohiro Morio, Ken Tabuchi, et al.
Ebiomedicine|February 13, 2021
Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemiaAnne P de Groot, Yoriko Saito, Eiryo Kawakami, et al.
Japanese Journal of Clinical Oncology|July 9, 2022
A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20)Daisuke Tomizawa, Shin-Ichi Tsujimoto, Shiro Tanaka, et al.
International Journal of Hematology|January 20, 2016
Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children's Cancer Study GroupDai Keino, Akitoshi Kinoshita, Daisuke Tomizawa, et al.
Journal of Hematology & Oncology|April 28, 2024
A higher CD34 + cell dose correlates with better event-free survival after KIR-ligand mismatched cord blood transplantation for childhood acute myeloid leukemiaHisashi Ishida, Yuta Kawahara, Daisuke Tomizawa, et al.
Genes, Chromosomes & Cancer|June 3, 2022
Quantitative assessment of copy number alterations by liquid biopsy for neuroblastomaRyota Shirai, Tomoo Osumi, Aiko Sato-Otsubo, et al.
Blood Advances|September 29, 2020
Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AMLHidemasa Matsuo, Kenichi Yoshida, Kana Nakatani, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 4, 2023
[Manufacturing results of tisagenlecleucel for acute lymphoblastic leukemia: a survey by the CAR-T cell therapy taskforce of the Japan Society of Transfusion Medicine and Cell Therapy]Tomoyasu Jo, Tomoko Henzan, Daisuke Tomizawa, et al.
Pageof 19

Showing results (131-140 of 188) with videos related to

Sort By:
Pageof 19
Bone Marrow Transplantation|May 26, 2018
Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemiaMotohiro Kato, Mio Kurata, Junya Kanda, et al.
Leukemia|February 16, 2021
Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndromeTakashi Taga, Shiro Tanaka, Daisuke Hasegawa, et al.
International Journal of Hematology|September 19, 2020
Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysisMiharu Yabe, Tomohiro Morio, Ken Tabuchi, et al.
Ebiomedicine|February 13, 2021
Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemiaAnne P de Groot, Yoriko Saito, Eiryo Kawakami, et al.
Japanese Journal of Clinical Oncology|July 9, 2022
A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20)Daisuke Tomizawa, Shin-Ichi Tsujimoto, Shiro Tanaka, et al.
International Journal of Hematology|January 20, 2016
Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children's Cancer Study GroupDai Keino, Akitoshi Kinoshita, Daisuke Tomizawa, et al.
Journal of Hematology & Oncology|April 28, 2024
A higher CD34 + cell dose correlates with better event-free survival after KIR-ligand mismatched cord blood transplantation for childhood acute myeloid leukemiaHisashi Ishida, Yuta Kawahara, Daisuke Tomizawa, et al.
Genes, Chromosomes & Cancer|June 3, 2022
Quantitative assessment of copy number alterations by liquid biopsy for neuroblastomaRyota Shirai, Tomoo Osumi, Aiko Sato-Otsubo, et al.
Blood Advances|September 29, 2020
Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AMLHidemasa Matsuo, Kenichi Yoshida, Kana Nakatani, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 4, 2023
[Manufacturing results of tisagenlecleucel for acute lymphoblastic leukemia: a survey by the CAR-T cell therapy taskforce of the Japan Society of Transfusion Medicine and Cell Therapy]Tomoyasu Jo, Tomoko Henzan, Daisuke Tomizawa, et al.
Pageof 19